Evidence map›Paper›PMID 39109436›Full record

ReviewFuture medicinal chemistry2024

Aminopyridines in the development of drug candidates against protozoan neglected tropical diseases.

Romain Mustière, Alexandra Dassonville-Klimpt, Pascal Sonnet

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Future medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Romain MustièreUniversité de Picardie-Jules-Verne, AGIR - Agents infectieux, RéSistance et chimiothérapie, UR 4294, UFR de pharmacie, 1, Rue des Louvels, F-80037 Amiens cedex 1, France.ORCID 0000-0002-1277-7728
Alexandra Dassonville-KlimptUniversité de Picardie-Jules-Verne, AGIR - Agents infectieux, RéSistance et chimiothérapie, UR 4294, UFR de pharmacie, 1, Rue des Louvels, F-80037 Amiens cedex 1, France.ORCID 0000-0002-2891-9102
Pascal SonnetUniversité de Picardie-Jules-Verne, AGIR - Agents infectieux, RéSistance et chimiothérapie, UR 4294, UFR de pharmacie, 1, Rue des Louvels, F-80037 Amiens cedex 1, France.ORCID 0000-0003-0118-9151

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neglected tropical diseases (NTDs) pose a major threat in tropical zones for impoverished populations. Difficulty of access, adverse effects or low efficacy limit the use of current therapeutic options. Therefore, development of new drugs against NTDs is a necessity. Compounds containing an aminopyridine (AP) moiety are of great interest for the design of new anti-NTD drugs due to their intrinsic properties compared with their closest chemical structures. Currently, over 40 compounds with an AP moiety are on the market, but none is used against NTDs despite active research on APs. The aim of this review is to present the medicinal chemistry work carried out with these scaffolds, against protozoan NTDs:

Indexed as

AminopyridinesAntiprotozoal AgentsNeglected DiseasesTrypanosoma brucei bruceiTrypanosoma cruziAnimalsDrug DevelopmentHumansLeishmaniaParasitic Sensitivity TestsAminopyridinesAntiprotozoal Agentsaminopyridinechagas diseasedrug designhuman african trypanosiomasisleischmaniasisneglected tropical diseasespharmacochemical propertiespharmacokinetic properties

Identifiers

PMID39109436
PMCPMC11318709

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.